A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
| Autor: | J. A Davis, Paul Vasey, Stan B. Kaye, V J O'Neill, James Paul, N. S. Reed |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2002 |
| Předmět: |
Adult
Diarrhea Cancer Research medicine.medical_specialty endocrine system diseases Paclitaxel medicine.medical_treatment advanced epithelial ovarian cancer Ovary Docetaxel urologic and male genital diseases Carboplatin Dose finding chemistry.chemical_compound Clinical Antineoplastic Combined Chemotherapy Protocols Carcinoma medicine dose-finding study Humans Epithelial ovarian cancer neoplasms Aged Gynecology Ovarian Neoplasms Chemotherapy Stomatitis Dose-Response Relationship Drug business.industry Middle Aged medicine.disease epirubicin female genital diseases and pregnancy complications medicine.anatomical_structure Oncology chemistry Area Under Curve Cancer research Female Taxoids business therapeutics Epirubicin medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | The docetaxel–carboplatin combination is active and well tolerated in patients with epithelial ovarian cancer. We added epirubicin to this combination to investigate additional benefits of anthracyclines in epithelial ovarian cancer. Twenty-one patients, FIGO Ic-IV, performance status 0–1, were treated in four dose cohorts. Docetaxel was fixed at 75 mg m−2, carboplatin doses were AUC 4–5 and epirubicin doses were 50–60 mg m−2. Drugs were given on day 1, every 3 weeks, except in cohort 3, where epirubicin was given on day 8. Dexamethasone was given prophylactically. One dose-limiting toxicity occurred in cohorts 1, 2 and 4, two occurred in cohort 3. Complicated neutropenia occurred in two patients in cohorts 1 and 2 and one patient in cohorts 3 and 4. Two patients experienced grade III diarrhoea or stomatitis in cohort 1 and two in cohort 3. There were no treatment-related deaths. Grade II sensory neuropathy occurred in one patient. No cardiac toxicity or significant oedema was observed. The overall response rate was 36%, and 62% were CA125 responders. The predefined maximum tolerated dose was exceeded in cohort 3. The cohort 4 dose level (epirubicin 50 mg m−2, carboplatin AUC 4, docetaxel 75 mg m−2), warrants further study. British Journal of Cancer (2002) 86, 1385–1390. DOI: 10.1038/sj/bjc/6600259 www.bjcancer.com © 2002 Cancer Research UK |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|